相关实验视频

Updated: Sep 14, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

源自内皮的C型尿素抵消了肺高血压的发病原因

Joshua P Dignam¹, Aisah A Aubdool¹, Vanessa R Lowe¹

¹William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.

Pharmacological research

|July 24, 2025

概括

C型尿素 (CNP) 通过调节血管改造和心脏功能来保护肺高血压 (PH). 准CNP途径为PH和右心室重塑提供了潜在的治疗策略.

科学领域:

心血管生物学心血管生物学
肺部医学肺部医学
分子心脏病学分子心脏病学

背景情况:

C型尿素 (CNP) 对于系统性平衡至关重要,影响血管重塑和心脏功能.
肺高血压 (PH) 涉及复杂的病理生物学,影响肺循环和右心室.
性受体 (NPR) 信号通路是心血管疾病治疗干预的潜在目标.

研究的目的:

在PH发育期间研究内源性CNP在肺循环和右心室的保护作用.
探索针对PH中的NPR信号的治疗潜力.
阐明内皮细胞和心肌细胞衍生的CNP对PH病变的具体贡献.

主要方法:

使用的淘汰赛小鼠模型 (内皮受限的CNP淘汰赛,心肌细胞特异的CNP淘汰赛,全球NPR-C淘汰赛) 暴露于PH的缺氧/苏根 (SuHx) 模型.
通过透式迷你向已确立PH的小鼠注射外源性CNP.
通过测量右心室缩压 (RVSP),右心室缩 (RVH) 和RV纤维化来评估PH严重程度.

主要成果:

在SuHx模型中,内皮特异性CNP缺陷加剧了PH发育,RVH和纤维化.
全球NPR-C缺乏特别恶化了RVH和纤维化,但不是RVSP.
特定于心肌细胞的CNP缺陷并没有显著改变PH表型.
外源CNP的使用有效地降低了RVSP,并促进了心肺抗重塑信号传递.

结论:

内源性CNP,特别是来自内皮来源的CNP,对肺高血压的发展和右心室重塑起着保护作用.
准依赖于CNP的NPR-B和NPR-C信号通路表明了管理PH和相关RV功能障碍的治疗潜力.

关键词:

这是一种天然尿素.纳利性受体的受体是什么肺高血压是一种肺高血压.右心室纤维化是什么血管改造是指进行血管改造.

更多相关视频

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Hormonal Regulation of Blood Pressure

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...